Zydus Lifesciences secures two final approvals from USFDA; stock slips ~1%

1 Sep 2022 , 01:32 PM

Zydus Lifesciences Limited (previously Cadila Healthcare Limited) received the final USFDA approval to market Venlafaxine Extended-Release Tablets, USP 37.5 mg, 75 mg, 150 mg, and 225 mg, and Pregabalin Extended-Release Tablets, USP 82.5 mg, 165 mg, and 330 mg.

Venlafaxine is a medication that is prescribed to treat depression, anxiety, panic attacks, and social anxiety disorder. It is anticipated to boost patients’ mood and energy levels. It is also believed that the medicine would reduce fear, anxiety, undesirable thoughts, and the number of panic episodes. The medicine would be produced at the group’s formulation manufacturing plant in Ahmedabad Special Economic Zone, India.

According to IQVIA MAT July 2022, Venlafaxine Extended-Release tablets had yearly sales of USD 46 million in the United States.

Pregabalin Extended-Release Tablets are used to relieve pain caused by diabetic nerve damage or shingles (herpes zoster) infection. The medicine would be produced at the group’s formulation manufacturing plant in Ahmedabad Special Economic Zone, India.

According to IQVIA MAT June 2022, Pregabalin Extended-Release tablets had yearly sales of USD 3 million in the United States.

Following receipt of these 2 approvals, the group now holds 322 USFDA approvals.

Zydus Lifesciences was trading at Rs373.70 down by 1.15% from its previous closing of Rs378.05 on the BSE. The scrip touched intraday high and low of Rs384.55 and Rs372.50 respectively.

For feedback and suggestions, write to us at [e-mail]